Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of XTR004 as a Novel 18F-labeled PET Myocardial Perfusion Imaging (MPI) Tracer in Diagnosis of Known or Suspected CAD Compared With Invasive Coronary Angiography, Fractional Flow Reserve, Index of Microcirculatory Resistance

NCT05885841 is registered in ClinicalTrials.gov with Sinotau Pharmaceutical Group as lead sponsor.

NCT NCT05885841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05885841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of XTR004 as a Novel 18F-labeled PET Myocardial Perfusion Imaging (MPI) Tracer in Diagnosis of Known or Suspected CAD Compared With Invasive Coronary Angiography, Fractional Flow Reserve, Index of Microcirculatory Resistance
Lead sponsor
Sinotau Pharmaceutical Group
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2022
Completion date
May 9, 2023
Enrollment
83 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease (cad)